INforMS – Page 7

- MAVENCLAD is the first oral MS treatment to provide two years of proven efficacy with a maximum of 20 days of treatment - MAVENCLAD's [...]

0

OHSU doctors part of ‘breakthrough’ research on treating multiple sclerosis

INforMS, Partners

PORTLAND, Ore. (KATU) – They're calling it a potential game-changer. Doctors at Oregon Health and Science University are part of a new [...]

0

Anne Cross, neurologist with pioneering work into B-cells/multiple sclerosis, awarded John Dystel Prize

INforMS, Partners

This year’s John Dystel Prize for Multiple Sclerosis Research is being awarded to Anne H. Cross, a neurologist and MS chair in the [...]

0

Novartis gets FDA approval for Mayzent (Siponimod), the first oral drug to treat SPMS

INforMS, Partners

EAST HANOVER, N.J., March 27, 2019 /PRNewswire/ --Novartis today announced that the US Food and Drug Administration (FDA) has approved [...]

0

Novartis receives FDA approval for MAYZENT (Siponimod)

INforMS, Partners

- Mayzent® (siponimod) is the first and only oral treatment specifically indicated for active secondary progressive multiple sclerosis [...]

0

Dose-finding study for SAR442168 in relapsing multiple sclerosis

INforMS

Brief Summary: Primary Objective: To determine the efficacy of SAR442168 in reducing the number of new brain lesions reported in [...]

0

BrainStorm announces first patient in phase 2 clinical trial progressive multiple sclerosis

INforMS

NEW YORK and CLEVELAND, March 14, 2019 (GLOBE NEWSWIRE)—BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing [...]

0

Depression, psychological distress symptoms affect multiple sclerosis patients’ quality of life

INforMS, MS Community

Depression and psychological distress symptoms can have a huge effect on the way multiple sclerosis (MS) patients view their well-being, [...]

0

FDA accepts BrainStorm’s NurOwn® IND application for progressive multiple sclerosis

INforMS

NEW YORK, Dec. 17, 2018 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of innovative [...]

0

Positive late-breaking phase II data evaluating investigational oral therapy

INforMS

First Bruton’s Tyrosine Kinase inhibitor (BTKi) demonstrating clinical proof-of-concept in relapsing multiple sclerosis (RMS) [...]

Elizabeth Porco

15

0

Category Archives: "INforMS"

Recent Posts

Contact Us